Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets

被引：15
作者：
Pospieszna, Julia [1 ]
Dams-Kozlowska, Hanna [2 ,3 ]
Udomsak, Wachirawit [1 ]
Murias, Marek [1 ,4 ]
Kucinska, Malgorzata [1 ]
机构：
[1] Poznan Univ Med Sci, Dept Toxicol, 30 Dojazd St,10 Uniwersytetu Poznanskiego St, PL-60631 Poznan, Poland
[2] Poznan Univ Med Sci, Dept Canc Immunol, 15 Garbary St, PL-61866 Poznan, Poland
[3] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, 15 Garbary St, PL-61866 Poznan, Poland
[4] Adam Mickiewicz Univ, Ctr Adv Technol, Uniwersytetu Poznanskiego 10 St, PL-61614 Poznan, Poland
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 13期
基金：
英国科研创新办公室;
关键词：
CD133; prominin-1; cancer stem cells; gene therapy; immunotherapy; nanotechnology; ANTI-CD133; MONOCLONAL-ANTIBODY; TUMOR-INITIATING CELLS; HEMATOPOIETIC STEM; SIGNALING PATHWAY; NEURAL STEM; LITHOCARPUS-POLYSTACHYUS; GOLD NANOPARTICLES; PROGENITOR CELLS; POOR-PROGNOSIS; GENE-TRANSFER;
D O I：
10.3390/ijms241310910
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Cancer remains a leading cause of death globally, and its complexity poses a significant challenge to effective treatment. Cancer stem cells and their markers have become key players in tumor growth and progression. CD133, a marker in various cancer types, is an active research area as a potential therapeutic target. This article explores the role of CD133 in cancer treatment, beginning with an overview of cancer statistics and an explanation of cancer stem cells and their markers. The rise of CD133 is discussed, including its structure, functions, and occurrence in different cancer types. Furthermore, the article covers CD133 as a therapeutic target, focusing on gene therapy, immunotherapy, and approaches to affect CD133 expression. Nanoparticles such as gold nanoparticles and nanoliposomes are also discussed in the context of CD133-targeted therapy. In conclusion, CD133 is a promising therapeutic target for cancer treatment. As research in this area progresses, it is hoped that CD133-targeted therapies will offer new and effective treatment options for cancer patients in the future.
引用
收藏
页数：29
相关论文
共 230 条
[21]  
Berg K., 2023, Photodiagnosis Photodyn. Ther, V41, DOI [10.1016/j.pdpdt.2023.103453, DOI 10.1016/J.PDPDT.2023.103453]
[22]   Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives [J].
Berois, Nora ;
Pittini, Alvaro ;
Osinaga, Eduardo .
CANCERS, 2022, 14 (03)
[23]   Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment [J].
Bertolini, Giulia ;
Roz, Luca ;
Perego, Paola ;
Tortoreto, Monica ;
Fontanella, Enrico ;
Gatti, Laura ;
Pratesi, Graziella ;
Fabbri, Alessandra ;
Andriani, Francesca ;
Tinelli, Stella ;
Roz, Elena ;
Caserini, Roberto ;
Lo Vullo, Salvatore ;
Camerini, Tiziana ;
Mariani, Luigi ;
Delia, Domenico ;
Calabro, Elisa ;
Pastorino, Ugo ;
Sozzi, Gabriella .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (38) :16281-16286
[24]   Differentiation of progenitors in the liver: a matter of local choice [J].
Boulter, Luke ;
Lu, Wei-Yu ;
Forbes, Stuart J. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (05) :1867-1873
[25]   CD133-targeted Gene Transfer Into Long-term Repopulating Hematopoietic Stem Cells [J].
Brendel, Christian ;
Goebel, Benjamin ;
Daniela, Abriss ;
Brugman, Martijn ;
Kneissl, Sabrina ;
Schwaeble, Joachim ;
Kaufmann, Kerstin B. ;
Mueller-Kuller, Uta ;
Kunkel, Hana ;
Chen-Wichmann, Linping ;
Abel, Tobias ;
Serve, Hubert ;
Bystrykh, Leonid ;
Buchholz, Christian J. ;
Grez, Manuel .
MOLECULAR THERAPY, 2015, 23 (01) :63-70
[26]   Role of CD133 Molecule in Wnt Response and Renal Repair [J].
Brossa, Alessia ;
Papadimitriou, Elli ;
Collino, Federica ;
Incarnato, Danny ;
Oliviero, Salvatore ;
Camussi, Giovanni ;
Bussolati, Benedetta .
STEM CELLS TRANSLATIONAL MEDICINE, 2018, 7 (03) :283-294
[27]   Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells [J].
Brown, Geoffrey .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
[28]   Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer [J].
Brown, Jason R. ;
Chan, Daniel K. ;
Shank, Jessica J. ;
Griffith, Kent A. ;
Fan, Huihui ;
Szulawski, Robert ;
Yang, Kun ;
Reynolds, R. Kevin ;
Johnston, Carolyn ;
McLean, Karen ;
Uppal, Shitanshu ;
Liu, J. Rebecca ;
Cabrera, Lourdes ;
Taylor, Sarah E. ;
Orr, Brian C. ;
Modugno, Francesmary ;
Mehta, Pooja ;
Bregenzer, Michael ;
Mehta, Geeta ;
Shen, Hui ;
Coffman, Lan G. ;
Buckanovich, Ronald J. .
JCI INSIGHT, 2020, 5 (11)
[29]   CD133 in Breast Cancer Cells: More than a Stem Cell Marker [J].
Brugnoli, Federica ;
Grassilli, Silvia ;
Al-Qassab, Yasamin ;
Capitani, Silvano ;
Bertagnolo, Valeria .
JOURNAL OF ONCOLOGY, 2019, 2019
[30]   Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling [J].
Chai, Xinqun ;
Chu, Hongpeng ;
Yang, Xuan ;
Meng, Yuanpu ;
Shi, Pengfei ;
Gou, Shanmiao .
SCIENTIFIC REPORTS, 2015, 5
12345678910